Johnson & Johnson Announces 1-Shot Vaccine is 66% Effective Against Moderate to Severe COVID-19
Summary from the AllSides News Team
Featured Coverage of this Story
From the Left
Johnson & Johnson’s Vaccine Offers Strong Protection but Fuels Concern About VariantsJohnson & Johnson, the only major drug maker developing a single-dose vaccine for Covid, announced on Friday that its shot provided strong protection against Covid-19, potentially offering another powerful tool in a desperate race against a worldwide rise in virus mutations.
But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases.
From the Left
Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19A global study of nearly 44,000 found that the COVID-19 vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease.
The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.
The South African results are troubling because of the coronavirus variant spreading there that has now been detected in the U.S., raising concerns...
From the Right
Johnson & Johnson Releases Single-Dose Vaccine ResultsJohnson & Johnson announced on Friday that its coronavirus vaccine was 72 percent effective against the pathogen in the U.S., and the company will ask federal regulators for approval in February.
Unlike the Pfizer-BioNTech and Moderna candidates, Johnson & Johnson’s vaccine is administered in one shot. The vaccine uses a relatively new technology to deliver a coronavirus gene into the body by using a modified form of the common cold. The gene instructs bodily cells to make a protein similar to coronavirus, which wards off infection.
AllSides Picks
March 28th, 2024
March 28th, 2024
March 27th, 2024